

---

## Hikma celebrates 40 years of Hatch-Waxman drug savings

---

**London, 30 September 2024** – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, has become one of the leading providers of high-quality generic medicines to millions of patients across the US, thanks to an important piece of legislation that marked its 40th anniversary last week.

The Drug Price Competition and Patent Term Restoration Act of 1984, better known as the Hatch-Waxman Act, is a US federal law that established the modern system for regulating generic drugs in the United States. The Act was signed into law on 24 September 1984, paving the way for companies like Hikma to provide Americans with broad access to a wide range of more affordable generic medicines.

According to the Association for Accessible Medicines (AAM), generic medicines saved US patients, employers, and taxpayers more than \$445 billion in 2023 alone, and more than \$3 trillion in savings the last ten years.

Hikma is proud to contribute to the 90% of all US prescriptions which are filled with generic or biosimilar medicines. As a leading generics company in North America, Europe and MENA, with a portfolio of more than 760 essential medicines and a strong and growing US manufacturing presence, Hikma is committed to providing patients around the world with reliable and affordable high-quality medicines.

Read AAM's 2024 U.S. Generic & Biosimilar Medicines Savings Report here: [2024 Savings Report | Association for Accessible Medicines \(accessiblemeds.org\)](#)

– ENDS –

### **About Hikma**

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)